Skip to content

Study · Randomized controlled trial · n = 82 · 2019

2 results

Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.

Zheng S, Liu E, Zhang Y, Long T, Liu X, Gong Y, Mai T, Shen H, Chen H, Lin R, Zheng Y, Xie Y, Wang F

Endocrine journal26 Mar 2019Cited by 22 (Europe PMC)

PMID30918134 (opens in a new tab)DOI10.1507/endocrj.ej18-0153 (opens in a new tab)PepBankPUB-30918134
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, circulating ZAG did not differ significantly between exenatide and metformin treatment.

    In plain wordsIn overweight or obese women with PCOS, circulating ZAG did not differ significantly between exenatide and metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCirculating zinc-α2-glycoprotein
    Study

    n = 82

    Comparator
    metformin
    Outcome group
    Blood biochemical markers · Metabolic and weight
    Studied dose
    10 μg twice daily · injection · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    however there was no statistical difference between the 2 treatments (p > 0.05).
    1 context sentence
    Summary · context
    Eighty-two overweight/obese subjects of the recruited women with PCOS were then randomly assigned to groups administered either 12 weeks of exenatide injection (10 μg b.i.d.) or oral metformin (1,000 mg b.i.d.).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, circulating ZAG rose from 46.54 to 56.41 ng/mL after 12 weeks of exenatide, as it also did with metformin.

    In plain wordsIn women with PCOS, blood ZAG levels rose from baseline with exenatide, and also with metformin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCirculating zinc-α2-glycoprotein
    Study

    n: not reported in source

    Comparator
    baseline
    Outcome group
    Blood biochemical markers · Metabolic and weight
    Studied dose
    10 μg twice daily · injection · 12 weeksAs given in this study (human).

    Measurements

    Circulating ZAG
    46.54 ng/mL
    exenatide group, baseline
    Circulating ZAG
    56.41 ng/mL
    exenatide group, after 12 weeks

    Source sentences

    Summary
    After 12 weeks of exenatide or metformin treatment, there were significant increases (p < 0.01) in circulating ZAG in both treatment groups
    Summary
    the exenatide baseline level was 46.54 ± 2.38 ng/mL vs. 56.41 ± 2.02 ng/mL after treatment, p < 0.01
    1 context sentence
    Summary · context
    Eighty-two overweight/obese subjects of the recruited women with PCOS were then randomly assigned to groups administered either 12 weeks of exenatide injection (10 μg b.i.d.) or oral metformin (1,000 mg b.i.d.).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.